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Abstract
The Early-7 (E7) protein of HPV binds to the underphosphorelated form of the tumor suppressor
protein – pRb and displaces the E2F transcription factor that is normally bound by pRb. The latent
membrane protein-1 (LMP-1) of EBV prevents apoptosis of B cells by up regulating the expression
of bcl-2, and it activates growth promoting pathway that are normally triggered by T cell – derivate
signal. The aims of this study to know that in cervical cancer stay HPV and EBV.
DNA was isolated from nineteen sample cervical cancer tissues frozen section. Diagnose related
with HPV and EBV was made by Polymerase Chains Reaction (PCR).
The result of this experiment showed that from 19 samples diagnosed as cervical cancer, 17
samples are positive HPV and 13 samples had HPV and EBV positive. The conclusion of this
experiment is 89% of cervical cancers are infected with HPV and 68% also infected with HPV and
EBV.
Introduction
The traditional way to diagnose tumors is by histopathol-
ogy stains and analysis. The diagnosis of cancer relies pri-
marily on invasive tissue biopsy [1]. The conventional
histopathology based on light microscopy, however, has
recently been complemented with ultrastructure, immu-
nohistochemistry and molecular diagnostics [2].
Cancer of the uterine cervix is the most common form of
cancer in women developing countries as leading cause of
cancer-related deaths in women in the world as a whole
[3]. Cervical cancer is stay as the first for cancer caused
death in Indonesia and still be a problem of health [4].
There are four human viruses that cause cancer in human.
There are papilloma viruses (PV), epstein barr viruses
(EBV), hepatitis B virus (HBV), and kaposi sarcoma her-
pes virus (KSHV) [3].
The E7 protein binds to the underphosphorelated form of
the tumor suppressor protein pRb and displaces the E2F
transcription factor that is normally bound by pRb
[3,5,6].
The latent membrane protein-1 (LMP-1) of EBV prevents
apoptosis of B cells by up regulating the expression of bcl-
2, and it activates growth promoting pathway that are nor-
mally triggered by T cell-derivated signal [3,5,6].
Materials and methods
Nineteen frozen section tissues are collected from obstet-
ric and gynecologic part of doctor Muwardi Hospital
Surakarta patient with cervical cancer from January 2001
to January 2002. DNA isolation was made by Henk
Schmits method with some modifications. Cut up to 25
mgr of tissue into small pieces, place in 1.5 ml a microfuge
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Add 20 ul of Proteinase K stock solution, mix by vortex-
ing, and incubate at 55°C overnight [7].
Diagnose related with HPV infections are made by Henk
Schmits and/or Nigel McMillan and Nina Fowler PCR-
method with some modifications [7,8]. Diagnose related
with EBV infections are made by Ausbel PCR-method with
some modifications [9]. Twenty five μl microfuge tube
Ready To Go PCR Bead (Amersham Pharmacia Biotech)
mixed with 2 μl HPV consensus primers (MY09 and
MY11) (CYBERGENE AB) and 2 μl DNA template the
other hand twenty five μl microfuge tube Ready To Go
PCR Bead (Amersham Pharmacia Biotech) mixed with 2
μl Ebna 3C5/Ebna 3C3 primers (CYBERGENE AB). PCR
protocol for both amplifications are 94°C for 50 seconds,
59°C for 50 seconds, 72°C for 50 seconds and 4°C soak.
The Amplification of HPV-L-1 gene produced 450 bp
long. The amplified EBV-Ebna 3C product is 153 bp long
as EBV1 and 246 bp as EBV2.
Result and discussion
The traditional way of classifying tumors is by histopa-
thology; the staining and analysis of tissue samples. Now,
the ability to analyze change in the levels of the transcripts
and/or protein products for literally thousands of genes
promises interesting possibilities as a research tool – for
understanding the underlying molecular mechanisms,
but also for automated tissue diagnosis [1,10]. The diag-
nosis of cancer relies primarily on invasive tissue biopsy,
as non invasive diagnostic test are generally insufficient to
define a disease process of cancer. Molecular medicine has
led to the discovery and application of molecular tumor
markers, which make histology more accurate and addi-
tionally help to prognosticate cancer. The diagnosis of
cancer involves the analysis of tissue and cytology speci-
mens obtained through several procedures, including sur-
gical biopsy, endoscopic biopsy, etc. Polymerase Chain
Reaction Method is the technique that based on detection
of specific sequences of gene targets by use the specific
primer [2,11,12].
The result of this experiment is from 19 cervical cancer
samples found 17 samples (89%) with HPV positive.
Neoplasm of the cervical uterine is the most common
form neoplasm in women [3,13-20]. This neoplasm is
found in developing state as leading cause of neoplasm-
related deaths in women in the world as a whole. The
mortality rate has been estimated at 2.8 deaths per
100.000 women, with a total of 252 deaths reported in
1993. Now the pathogenesis of cervical cancer is pointed
to HPV. Human papilloma virus infection associated with
malignancies of urogenital tract and anus. He also
thought to be related to disorder of skin and the upper-
respiratory tract. Many studies suggest that cervical cancer
is caused by sexual transmitted agents, and HPV is a prime
suspect [3].
More than 85% of invasive squamous cell cancer infected
by HPV types 16 and 18 and, less commonly, types 31, 33,
35, and 51. The affinity of these viral proteins for the
products of tumor suppressor genes differs depending on
the oncogenic potential of HPV. Early-6 and E7 proteins
derived from high-risk HPV bind to pRb and p53 with
high affinity. The Early-6 protein of HPV binds to and
facilitates the degradation of the p53 gene product. The
Early-7 protein binds to the underphosphorelated form of
the tumor suppressor protein pRb and displaces the E2F
transcription factor that are normally bound by pRb
[3,5,6].
Human papilloma viruses as an oncogenic virus are well
characterized viruses that play role in cervical cancer.
However there are possible that other viruses might also
involve in this cancer incidence [3,13-21].
The gel electrophoresis from PCR product to amplified of L-1 gene (450 bps long) of HPV in cervical cancer samplesFigur 1
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HPV positive found 13 samples had also EBV positive.
Epstein-Barr viruses known involve in many malignancy
cases such as nasopharyngeal carcinoma, limphoma
maligna, Burkitts limphoma, Hodgkins disease and gas-
tric carcinoma. It is known that EBV also infected squa-
mous cells [3,13,22-25].
There is increasing evidence that among the concequences
of viral infection are influence on cell survival which
result from inference, by viral elements, with the normal
regulation of apoptosis. Epstein-Barr virus enhancing the
survival of B cells via the number of mechanism. Of these,
conversion of cell from bcl-2 negative to bcl-2 positive
through to transactivating ability of the latent EBV gene
LMP-1 and EBNA-2, provides the virus with a strategy for
survival during the germinal centre stage of B cell develop-
ment when expression of bcl-2 protein is normally down
regulated [3,5].
From this experiment we found 13 samples (68%) had
HPV and EBV positive. Our conclusion is expected HPV
may be EBV also involve in carcinogenesis of cervical can-
cer.
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